HUP9904052A3 - Monoclonal antibodies againts the extracellular domain of human vegf-receptor protein (kdr) - Google Patents

Monoclonal antibodies againts the extracellular domain of human vegf-receptor protein (kdr)

Info

Publication number
HUP9904052A3
HUP9904052A3 HU9904052A HUP9904052A HUP9904052A3 HU P9904052 A3 HUP9904052 A3 HU P9904052A3 HU 9904052 A HU9904052 A HU 9904052A HU P9904052 A HUP9904052 A HU P9904052A HU P9904052 A3 HUP9904052 A3 HU P9904052A3
Authority
HU
Hungary
Prior art keywords
againts
kdr
monoclonal antibodies
extracellular domain
receptor protein
Prior art date
Application number
HU9904052A
Other languages
English (en)
Original Assignee
Schering Ag
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Schering Ag filed Critical Schering Ag
Publication of HUP9904052A2 publication Critical patent/HUP9904052A2/hu
Publication of HUP9904052A3 publication Critical patent/HUP9904052A3/hu

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2863—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against receptors for growth factors, growth regulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K51/00—Preparations containing radioactive substances for use in therapy or testing in vivo
    • A61K51/02—Preparations containing radioactive substances for use in therapy or testing in vivo characterised by the carrier, i.e. characterised by the agent or material covalently linked or complexing the radioactive nucleus
    • A61K51/04—Organic compounds
    • A61K51/08—Peptides, e.g. proteins, carriers being peptides, polyamino acids, proteins
    • A61K51/10—Antibodies or immunoglobulins; Fragments thereof, the carrier being an antibody, an immunoglobulin or a fragment thereof, e.g. a camelised human single domain antibody or the Fc fragment of an antibody
    • A61K51/1027—Antibodies or immunoglobulins; Fragments thereof, the carrier being an antibody, an immunoglobulin or a fragment thereof, e.g. a camelised human single domain antibody or the Fc fragment of an antibody against receptors, cell-surface antigens or cell-surface determinants
    • A61K51/103—Antibodies or immunoglobulins; Fragments thereof, the carrier being an antibody, an immunoglobulin or a fragment thereof, e.g. a camelised human single domain antibody or the Fc fragment of an antibody against receptors, cell-surface antigens or cell-surface determinants against receptors for growth factors or receptors for growth regulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/04—Antineoplastic agents specific for metastasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Immunology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biophysics (AREA)
  • Optics & Photonics (AREA)
  • Rheumatology (AREA)
  • Epidemiology (AREA)
  • Physics & Mathematics (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • Genetics & Genomics (AREA)
  • Cardiology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Oncology (AREA)
  • Dermatology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Pain & Pain Management (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Peptides Or Proteins (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
HU9904052A 1996-09-11 1997-09-09 Monoclonal antibodies againts the extracellular domain of human vegf-receptor protein (kdr) HUP9904052A3 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
DE19638745A DE19638745C2 (de) 1996-09-11 1996-09-11 Monoklonale Antikörper gegen die extrazelluläre Domäne des menschlichen VEGF - Rezeptorproteins (KDR)
PCT/EP1997/004928 WO1998011223A1 (en) 1996-09-11 1997-09-09 Monoclonal antibodies against the extracellular domain of human vegf-receptor protein (kdr)

Publications (2)

Publication Number Publication Date
HUP9904052A2 HUP9904052A2 (hu) 2000-03-28
HUP9904052A3 true HUP9904052A3 (en) 2002-01-28

Family

ID=7806450

Family Applications (1)

Application Number Title Priority Date Filing Date
HU9904052A HUP9904052A3 (en) 1996-09-11 1997-09-09 Monoclonal antibodies againts the extracellular domain of human vegf-receptor protein (kdr)

Country Status (12)

Country Link
US (1) US6344339B1 (hu)
EP (1) EP0925359A1 (hu)
JP (1) JP2001501920A (hu)
AU (1) AU730287B2 (hu)
CA (1) CA2265927A1 (hu)
DE (1) DE19638745C2 (hu)
HU (1) HUP9904052A3 (hu)
IL (1) IL128406A0 (hu)
NO (1) NO991162L (hu)
PL (1) PL332034A1 (hu)
WO (1) WO1998011223A1 (hu)
ZA (1) ZA978204B (hu)

Families Citing this family (94)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2299099A (en) * 1998-02-04 1999-08-23 Kyowa Hakko Kogyo Co. Ltd. Antibodies against human vegf receptor kdr
DE19813774A1 (de) * 1998-03-27 1999-09-30 Max Planck Gesellschaft Parapockenvirus-kodierter vaskulärer Endothelzell Wachstumsfaktor (PPV-VEGF)
NO983911D0 (no) * 1998-08-26 1998-08-26 Norsk Hydro As Alginatkapsler til bruk ved behandling av hjernesvulst
PL348163A1 (en) * 1998-11-06 2002-05-06 Basf Ag Inhibition of the formation of vascular hyperpermeability
JP2002536968A (ja) * 1999-01-29 2002-11-05 イムクローン システムズ インコーポレイティド Ｋｄｒに特異的な抗体およびその使用
EP1130032A1 (en) * 2000-02-28 2001-09-05 Gesellschaft für biotechnologische Forschung mbH (GBF) Single-chain antibodies recognizing the human vascular endothelial growth factor receptor-2 (VEGFR-2/KDR)
SI2762140T1 (sl) 2001-02-19 2017-07-31 Novartis Ag Zdravljenje trdnih možganskih tumorjev z derivatom rapamicina
DE60219617T2 (de) 2001-05-16 2008-01-03 Novartis Ag Kombination von n- 5- 4-(4-methyl-piperazino-methyl)-benzoylamido -2-methylphenyl -4-(3-pyridil)-2pyrimidine-amin mit einem biphosphonat
TWI315982B (en) 2001-07-19 2009-10-21 Novartis Ag Combinations comprising epothilones and pharmaceutical uses thereof
GB0124317D0 (en) * 2001-10-10 2001-11-28 Celltech R&D Ltd Biological products
GB0206215D0 (en) 2002-03-15 2002-05-01 Novartis Ag Organic compounds
MXPA04011384A (es) 2002-05-16 2005-02-14 Novartis Ag Uso de agentes de union del receptor edg en cancer.
DK2261249T3 (en) 2002-09-12 2015-02-16 Oncotherapy Science Inc KDR peptides and vaccines comprising the same
US7250289B2 (en) * 2002-11-20 2007-07-31 Affymetrix, Inc. Methods of genetic analysis of mouse
AR044402A1 (es) 2003-05-19 2005-09-14 Irm Llc Compuestos heterociclicos y su uso como inmunodepresores. composiciones farmaceuticas que los contienen.
MY150088A (en) 2003-05-19 2013-11-29 Irm Llc Immunosuppressant compounds and compositions
GB0400122D0 (en) * 2004-01-06 2004-02-11 Badrilla Ltd Method of quantifying binding
GB0512324D0 (en) 2005-06-16 2005-07-27 Novartis Ag Organic compounds
EP2377555A3 (en) 2004-11-18 2011-11-23 Imclone LLC Antibodies against vascular endothelial growth factor receptor-1
US20060222595A1 (en) * 2005-03-31 2006-10-05 Priyabrata Mukherjee Nanoparticles for therapeutic and diagnostic applications
GB0510390D0 (en) 2005-05-20 2005-06-29 Novartis Ag Organic compounds
JP2009510073A (ja) 2005-09-27 2009-03-12 ノバルティス アクチエンゲゼルシャフト カルボキシアミン化合物およびその使用方法
NO20220050A1 (no) 2005-11-21 2008-08-12 Novartis Ag Neuroendokrin tumorbehandling
CN1987468B (zh) * 2005-12-23 2012-01-11 上海交通大学医学院附属仁济医院 血管内皮生长因子时间分辨荧光免疫分析方法及试剂盒
JP2009532503A (ja) 2006-04-05 2009-09-10 ノバルティス アクチエンゲゼルシャフト 癌を処置するための治療剤の組合せ
AU2007247112B2 (en) 2006-05-09 2010-08-26 Novartis Ag Combination comprising an iron chelator and an anti-neoplastic agent and use thereof
GB0612721D0 (en) 2006-06-27 2006-08-09 Novartis Ag Organic compounds
WO2008037477A1 (en) 2006-09-29 2008-04-03 Novartis Ag Pyrazolopyrimidines as p13k lipid kinase inhibitors
AU2007325931A1 (en) 2006-11-02 2008-06-05 Yale University Assessment of oocyte competence
WO2008093246A2 (en) * 2007-02-02 2008-08-07 Vegenics Limited Vegf receptor antagonist for treating organ transplant alloimmunity and arteriosclerosis
WO2008100985A2 (en) 2007-02-15 2008-08-21 Novartis Ag Combination of lbh589 with other therapeutic agents for treating cancer
TWI436775B (zh) 2007-08-24 2014-05-11 Oncotherapy Science Inc 以抗原胜肽合併化療藥劑治療胰臟癌
PL2260020T3 (pl) 2008-03-26 2015-01-30 Novartis Ag Hydroksamianowe inhibitory deacetylaz B
WO2010005527A1 (en) 2008-06-30 2010-01-14 Angioblast Systems, Inc. Treatment of eye diseases and excessive neovascularization using a combined therapy
EP2344161B1 (en) 2008-10-16 2018-12-19 Celator Pharmaceuticals, Inc. Combinations of a liposomal water-soluble camptothecin with cetuximab or bevacizumab
CA2743057C (en) * 2008-11-07 2019-11-26 Research Development Foundation Compositions and methods for the inhibition of cripto/grp78 complex formation and signaling
CN103204794A (zh) 2008-12-18 2013-07-17 诺瓦提斯公司 新的盐
BRPI0922457A2 (pt) 2008-12-18 2015-12-15 Novartis Ag forma polimórfica de ácido 1-(4-{1-[(e)-4-ciclo-hexil-3-trifluormetil-benziloxi-imino]-etil)-2-etil-benzil)-azetidino-3-carboxílico"
KR20110096584A (ko) 2008-12-18 2011-08-30 노파르티스 아게 1-［4-［1-(4-시클로헥실-3-트리플루오로메틸-벤질옥시이미노)-에틸］-2-에틸-벤질］-아제티딘-3-카르복실산의 헤미푸마레이트 염
SI2391366T1 (sl) 2009-01-29 2013-01-31 Novartis Ag Substituirani benzimidazoli za zdravljenje astrocitomov
TW201109029A (en) 2009-06-11 2011-03-16 Oncotherapy Science Inc Vaccine therapy for choroidal neovascularization
UA105794C2 (uk) 2009-06-26 2014-06-25 Новартіс Аг 1,3-ДИЗАМІЩЕНІ ПОХІДНІ ІМІДАЗОЛІДИН-2-ОНУ ЯК ІНГІБІТОРИ Cyp17
US8389526B2 (en) 2009-08-07 2013-03-05 Novartis Ag 3-heteroarylmethyl-imidazo[1,2-b]pyridazin-6-yl derivatives
WO2011018454A1 (en) 2009-08-12 2011-02-17 Novartis Ag Heterocyclic hydrazone compounds and their uses to treat cancer and inflammation
CA2771532C (en) 2009-08-17 2021-03-23 Intellikine, Inc. Heterocyclic compounds and uses thereof
IN2012DN01453A (hu) 2009-08-20 2015-06-05 Novartis Ag
BR112012008075A2 (pt) 2009-08-26 2016-03-01 Novartis Ag compostos de heteroarila tetrassubstituídos e seu uso como moduladores de mdm2 e/ou mdm4
CA2773661A1 (en) 2009-09-10 2011-03-17 Novartis Ag Ether derivatives of bicyclic heteroaryls
MX2012005293A (es) 2009-11-04 2012-06-19 Novartis Ag Derivados de sulfonamida heterociclicos utiles como inhibidores de mek.
CN102712648A (zh) 2009-11-25 2012-10-03 诺瓦提斯公司 双环杂芳基的与苯稠合的6元含氧杂环衍生物
CN102648188A (zh) 2009-12-08 2012-08-22 诺瓦提斯公司 杂环磺酰胺衍生物
CU24130B1 (es) 2009-12-22 2015-09-29 Novartis Ag Isoquinolinonas y quinazolinonas sustituidas
US8440693B2 (en) 2009-12-22 2013-05-14 Novartis Ag Substituted isoquinolinones and quinazolinones
JP2013532149A (ja) 2010-06-17 2013-08-15 ノバルティス アーゲー ピペリジニル置換１，３−ジヒドロ−ベンゾイミダゾール−２−イリデンアミン誘導体
EP2582680A1 (en) 2010-06-17 2013-04-24 Novartis AG Biphenyl substituted 1,3-dihydro-benzoimidazol-2-ylideneamine derivatives
EP2627648A1 (en) 2010-09-16 2013-08-21 Novartis AG 17aHYDROXYLASE/C17,20-LYASE INHIBITORS
WO2012107500A1 (en) 2011-02-10 2012-08-16 Novartis Ag [1, 2, 4] triazolo [4, 3 -b] pyridazine compounds as inhibitors of the c-met tyrosine kinase
WO2012116237A2 (en) 2011-02-23 2012-08-30 Intellikine, Llc Heterocyclic compounds and uses thereof
EP2683722A1 (en) 2011-03-08 2014-01-15 Novartis AG Fluorophenyl bicyclic heteroaryl compounds
MX359399B (es) 2011-04-28 2018-09-27 Novartis Ag Inhibidores de 17alfa-hidroxilasa/c17-20-liasa.
KR20140034898A (ko) 2011-06-09 2014-03-20 노파르티스 아게 헤테로시클릭 술폰아미드 유도체
US8859535B2 (en) 2011-06-20 2014-10-14 Novartis Ag Hydroxy substituted isoquinolinone derivatives
EP2721007B1 (en) 2011-06-20 2015-04-29 Novartis AG Cyclohexyl isoquinolinone compounds
JP2015527869A (ja) 2011-08-26 2015-09-24 メリマック ファーマシューティカルズ インコーポレーティッド タンデムＦｃ二重特異性抗体
ES2691650T3 (es) 2011-09-15 2018-11-28 Novartis Ag 3-(quinolin-6-il-tio)-[1,2,4]-triazolo-[4,3-a]-piridinas 6-sustituidas como inhibidores de tirosina quinasa c-Met
WO2013080141A1 (en) 2011-11-29 2013-06-06 Novartis Ag Pyrazolopyrrolidine compounds
MX2014007725A (es) 2011-12-23 2015-01-12 Novartis Ag Compuestos para inhibir la interaccion de bcl2 con los componentes de enlace.
AU2012355624A1 (en) 2011-12-23 2014-07-17 Novartis Ag Compounds for inhibiting the interaction of BCL2 with binding partners
CN104125954A (zh) 2011-12-23 2014-10-29 诺华股份有限公司 用于抑制bcl2与结合配偶体相互作用的化合物
CA2859862A1 (en) 2011-12-23 2013-06-27 Novartis Ag Compounds for inhibiting the interaction of bcl2 with binding partners
CN104136429A (zh) 2011-12-23 2014-11-05 诺华股份有限公司 用于抑制bcl2与结合配偶体相互作用的化合物
UY34591A (es) 2012-01-26 2013-09-02 Novartis Ag Compuestos de imidazopirrolidinona
EP2834246B1 (en) 2012-04-03 2021-07-28 Novartis AG Combination products with tyrosine kinase inhibitors and their use
JP6171003B2 (ja) 2012-05-24 2017-07-26 ノバルティス アーゲー ピロロピロリジノン化合物
WO2014115077A1 (en) 2013-01-22 2014-07-31 Novartis Ag Substituted purinone compounds
US9556180B2 (en) 2013-01-22 2017-01-31 Novartis Ag Pyrazolo[3,4-d]pyrimidinone compounds as inhibitors of the P53/MDM2 interaction
EA201591652A1 (ru) 2013-03-06 2016-02-29 Мерримак Фармасьютикалз, Инк. ТАНДЕМНЫЕ БИСПЕЦИФИЧЕСКИЕ Fc-АНТИТЕЛА ПРОТИВ c-MET
WO2014151147A1 (en) 2013-03-15 2014-09-25 Intellikine, Llc Combination of kinase inhibitors and uses thereof
WO2014155268A2 (en) 2013-03-25 2014-10-02 Novartis Ag Fgf-r tyrosine kinase activity inhibitors - use in diseases associated with lack of or reduced snf5 activity
EP2994758B1 (en) 2013-05-08 2017-12-20 Opthea Limited Biomarkers for age-related macular degeneration (amd)
WO2015022664A1 (en) 2013-08-14 2015-02-19 Novartis Ag Compounds and compositions as inhibitors of mek
WO2015022663A1 (en) 2013-08-14 2015-02-19 Novartis Ag Compounds and compositions as inhibitors of mek
US9227969B2 (en) 2013-08-14 2016-01-05 Novartis Ag Compounds and compositions as inhibitors of MEK
WO2015084804A1 (en) 2013-12-03 2015-06-11 Novartis Ag Combination of mdm2 inhibitor and braf inhibitor and their use
WO2015191602A2 (en) * 2014-06-09 2015-12-17 Biomed Valley Discoveries, Inc. Combination therapies targeting tumor-associated stroma or tumor cells
CA2954862A1 (en) 2014-07-31 2016-02-04 Novartis Ag Combination therapy
MX2017004007A (es) 2014-09-28 2018-05-07 Univ California Modulacion de celulas mieloides estimulantes y no estimulantes.
WO2017139417A1 (en) 2016-02-08 2017-08-17 Vitrisa Therapeutics, Inc. Compositions with improved intravitreal half-life and uses thereof
US10543231B2 (en) 2017-05-19 2020-01-28 Mayo Foundation For Medical Education And Research Methods and materials for treating cancer
CN111108120A (zh) * 2017-07-03 2020-05-05 财团法人生物技术开发中心 抗人类血管内皮生长因子受体的抗体及其应用
CA3079076A1 (en) 2017-10-18 2019-04-25 Chemotherapeutisches Forschungsinstitut Georg-Speyer-Haus Methods and compounds for improved immune cell therapy
AU2018383709A1 (en) 2017-12-12 2020-07-16 Pionyr Immunotherapeutics, Inc. Anti-TREM2 antibodies and related methods
EP3730483B1 (en) 2017-12-21 2023-08-30 Hefei Institutes of Physical Science, Chinese Academy of Sciences Class of pyrimidine derivative kinase inhibitors
US20220395553A1 (en) 2019-11-14 2022-12-15 Cohbar, Inc. Cxcr4 antagonist peptides

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN1173991C (zh) 1992-11-13 2004-11-03 马克斯普朗克科学促进协会 作为血管内皮生长因子受体的f1k-1
US5861499A (en) * 1994-02-10 1999-01-19 Imclone Systems Incorporated Nucleic acid molecules encoding the variable or hypervariable region of a monoclonal antibody that binds to an extracellular domain
US5840301A (en) 1994-02-10 1998-11-24 Imclone Systems Incorporated Methods of use of chimerized, humanized, and single chain antibodies specific to VEGF receptors

Also Published As

Publication number Publication date
JP2001501920A (ja) 2001-02-13
US6344339B1 (en) 2002-02-05
HUP9904052A2 (hu) 2000-03-28
NO991162L (no) 1999-05-06
DE19638745A1 (de) 1998-03-12
ZA978204B (en) 1998-03-03
IL128406A0 (en) 2000-01-31
DE19638745C2 (de) 2001-05-10
AU730287B2 (en) 2001-03-01
NO991162D0 (no) 1999-03-10
PL332034A1 (en) 1999-08-16
AU4622297A (en) 1998-04-02
EP0925359A1 (en) 1999-06-30
WO1998011223A1 (en) 1998-03-19
CA2265927A1 (en) 1998-03-19

Similar Documents

Publication Publication Date Title
HUP9904052A3 (en) Monoclonal antibodies againts the extracellular domain of human vegf-receptor protein (kdr)
IL136335A0 (en) Monoclonal human natural antibodies
ATE348113T1 (de) Rekombinanter anti-cd4 antikörper zur menschlichen behandlung
AU1462300A (en) Human pan-hcv human monoclonal antibodies
HUP1500179A2 (en) The use of human tnf-alpha binding antibodies
DK1516629T3 (da) Humaniseret anti-CD-11a antibodies
EP0977991A4 (en) MONOCLONAL ANTIBODIES FOR HUMAN CD6
IL122404A0 (en) High affinity human monoclonal antibodies specific for rsv f-protein
EE200000164A (et) Inimkeha tasakaalu taastamise aparaat
GR3034332T3 (en) Protein purification.
DE69531958D1 (de) (1-3)-beta-d-glukon-bindungsprotein, antikörper der dieses protein erkennt undverwendung des proteins und antikörper
EP0871661A4 (en) NEW PROTEIN DOMAIN BINDING TYROSIN PHARPHORYLIARTE PROTEINS
AU2299099A (en) Antibodies against human vegf receptor kdr
EP0977590A4 (en) HUMAN MONOCLONAL ANTIBODIES
EP0749445A4 (en) ANTIBODIES FOR FIXING TO THE EXTRACELLULAR DOMAIN OF G-CSF GRANULOCYTE GROWTH RECEPTOR RECEPTOR AND METHODS OF TREATMENT
EP0999848A4 (en) CHIMEAN PROTEINS FOR TREATING DIABETES
HUP9901204A3 (en) Novel protein hmw human mp52
AU6330598A (en) Novel human transmembrane 4 superfamily protein
EP0674003A3 (en) Modulators of receptors in the human central nervous system.
FR2747308B1 (fr) Association de margousier, de (-) hydroxycitrate et de ceramides et compositions les renfermant
BR9709080A (pt) Anticorpo monoclonal anti-MP52 humano
ZA978233B (en) The use of protein as anti-retroviral agents.
IL139595A0 (en) Human protein c polypeptide
DE69615850D1 (de) G-protein-gekoppelter rezeptor hnfd578
DE69434900D1 (de) Menschliche chemokin-polypeptide